Reviewer's report

Title: Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain

Version: 2
Date: 2 June 2014

Reviewer: Domenico Capone

Reviewer's report:

The manuscript deals with an interesting aspect in the treatment of mycotic infections in haematological disorders. The data are clearly presented and discussed and represents a further useful contribution to literature data for this issue. As it is well known the inhibitory effect of voriconazole on cytochrome P450 system, particularly for the isoform 3A4, I recommend to add the potential drug-drug interaction for this azole agent (see: 1) Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors. Curr Drug Metab. 2011 Mar;12(3):253-67; 2) Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm Ther. 2010 Feb;35(1):121-4.). Obviously, I recommend to add the two references in the appropriate sections.